NasdaqCM:PTE

Stock Analysis Report

Executive Summary

PolarityTE, Inc., a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States.

Snowflake

Fundamentals

Fair value with mediocre balance sheet.

Share Price & News

How has PolarityTE's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

10.9%

PTE

4.6%

US Biotechs

3.4%

US Market


1 Year Return

-79.5%

PTE

-10.1%

US Biotechs

5.4%

US Market

Return vs Industry: PTE underperformed the US Biotechs industry which returned -10.1% over the past year.

Return vs Market: PTE underperformed the US Market which returned 5.4% over the past year.


Shareholder returns

PTEIndustryMarket
7 Day10.9%4.6%3.4%
30 Day-30.9%-2.4%-1.0%
90 Day-41.8%-2.1%-0.4%
1 Year-79.5%-79.5%-9.4%-10.1%7.7%5.4%
3 Year-2.2%-2.2%14.9%10.9%46.2%36.8%
5 Year-17.3%-41.7%2.3%-2.7%65.6%47.5%

Price Volatility Vs. Market

How volatile is PolarityTE's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is PolarityTE undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: PTE ($3.15) is trading below our estimate of fair value ($74.63)

Significantly Undervalued: PTE is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PTE is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: PTE is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate PTE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PTE is good value based on its PB Ratio (1.1x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is PolarityTE forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

19.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PTE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PTE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PTE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PTE's revenue (65% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: PTE's revenue (65% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if PTE's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has PolarityTE performed over the past 5 years?

-46.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: PTE is unprofitable, and losses have increased over the past 5 years at a rate of -46.6% per year.

Accelerating Growth: Unable to compare PTE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PTE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: PTE has a negative Return on Equity (-189.15%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: PTE is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: PTE is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is PolarityTE's financial position?


Financial Position Analysis

Short Term Liabilities: PTE's short term assets ($61.8M) exceeds its short term liabilities ($9.2M)

Long Term Liabilities: PTE's short term assets (61.8M) exceeds its long term liabilities (5.4M)


Debt to Equity History and Analysis

Debt Level: PTE's debt to equity ratio (1.1%) is considered satisfactory

Reducing Debt: Insufficient data to determine if PTE's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: PTE has a high level of physical assets or inventory.

Debt Coverage by Assets: PTE's debt is covered by short term assets (assets are 79.903100x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PTE has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: PTE has less than a year of cash runway if free cash flow continues to reduce at historical rates of -97.3% each year


Next Steps

Dividend

What is PolarityTE's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate PTE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PTE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if PTE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PTE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PTE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of PolarityTE's salary, the management and board of directors tenure and is there insider trading?

1.3yrs

Average management tenure


CEO

PolarityTE has no CEO, or we have no data on them.


Management Age and Tenure

1.3yrs

Average Tenure

49yo

Average Age

Experienced Management: PTE's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Age and Tenure

2.8yrs

Average Tenure

60yo

Average Age

Experienced Board: PTE's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$11,31513 Jun 19
Edward Swanson
EntityIndividual
Role
Senior Key Executive
Chief Translational Medicine Officer
Shares2,000
Max PriceUS$5.66
SellUS$318,97812 Jun 19
Steven Gorlin
EntityIndividual
Shares53,700
Max PriceUS$5.94
BuyUS$11,36706 Jun 19
Edward Swanson
EntityIndividual
Role
Senior Key Executive
Chief Translational Medicine Officer
Shares2,000
Max PriceUS$5.68
BuyUS$207,55006 Jun 19
David Seaburg
EntityIndividual
Role
President
President & Member of Office of Chief Executive
Shares35,000
Max PriceUS$5.93
BuyUS$186,51906 Jun 19
Paul Mann
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares35,000
Max PriceUS$5.33
BuyUS$84,47106 Jun 19
Peter Cohen
EntityIndividual
Role
Chairman of the Board
Independent Chairman of the Board
Shares15,000
Max PriceUS$5.63

Ownership Breakdown


Management Team

  • Paul Mann

    Chief Financial Officer

    • Tenure: 1.3yrs
  • Mark Lehman

    Chief Legal Officer

    • Tenure: 0yrs
  • David Seaburg (49yo)

    President & Member of Office of Chief Executive

    • Tenure: 0.2yrs
  • Richard Hague (59yo)

    Chief Operating Officer

    • Tenure: 0.5yrs
  • Ned Swanson (34yo)

    Chief Translational Medicine Officer

    • Tenure: 0.5yrs
  • Holly Kramen

    Chief Compliance Officer & Privacy Officer

    • Tenure: 1.9yrs
  • Rich Haerle

    Vice President of Investor Relations & Strategy

    • Tenure: 1.4yrs
  • Alain Adam

    Vice President of Sales

    • Tenure: 1.3yrs
  • Nikolai Sopko

    Chief Scientific Officer and VP of R&D

    • Tenure: 1.3yrs
  • David Blum

    Chief Design & Technology Officer

    • Tenure: 0yrs

Board Members

  • Peter Cohen (72yo)

    Independent Chairman of the Board

    • Tenure: 0.08yrs
  • Michael Callahan

    Member of Clinical Advisory board

    • Tenure: 0yrs
  • Stephen Milner (70yo)

    Chief Clinical Officer & Member of Clinical Advisory Board

    • Tenure: 2.8yrs
  • Jon Mogford (50yo)

    Independent Director

    • Tenure: 2.7yrs
  • Michael Grant

    Member of Clinical Advisory Board

    • Tenure: 2.8yrs
  • Anand Kumar

    Member of Clinical Advisory Board

    • Tenure: 2.8yrs
  • Michael Neumeister (57yo)

    Chief Medical Officer & Member of Clinical Advisory Board

    • Tenure: 0yrs
  • Jeff Dyer (60yo)

    Independent Director

    • Tenure: 2.6yrs
  • Anthony Tufaro

    Member of Clinical Advisory Board

    • Tenure: 0yrs
  • Maurice Nahabedian

    Chief Surgical Officer & Member of Clinical Advisory Board

    • Tenure: 0yrs

Company Information

PolarityTE, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PolarityTE, Inc.
  • Ticker: PTE
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$79.794m
  • Shares outstanding: 25.33m
  • Website: https://www.polarityte.com

Number of Employees


Location

  • PolarityTE, Inc.
  • 123 North Wright Brothers Drive
  • Salt Lake City
  • Utah
  • 84116
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PTENasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDDec 2003
NJTCDB (Deutsche Boerse AG)YesCommon StockDEEURDec 2003

Biography

PolarityTE, Inc., a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicin ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/15 23:52
End of Day Share Price2019/10/15 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.